Thalassemia Patients in Peril as Critical Drug Vanishes from Government Hospitals
For 31-year-old Aman (name changed), his medical treatment is not a matter of choice but a daily battle for survival. The one medication that enables him to combat thalassemia effectively—Desferal injections—is consistently missing from government hospital supplies, creating a dire situation for him and thousands of others.
The High Cost of Survival
"We are not receiving Desferal injections regularly through government channels, and purchasing them privately comes at an exorbitant price," Aman explained. "A single box costs approximately Rs 2,900 and lasts merely a few days. Since we require continuous administration to eliminate excess iron from repeated blood transfusions, skipping doses is simply not an option."
This distressing scenario is echoed across major government healthcare facilities. Amit (name changed), a 37-year-old patient undergoing treatment at Lady Hardinge Medical College (LHMC), requires three vials daily, five days each week. Similarly, Sanjay, receiving care at LNJP Hospital, needs four vials every day. For both individuals, the financial burden becomes unsustainable when the drug is unavailable through public healthcare systems.
A Persistent Problem Spanning Years
Mayank Arora, another thalassemia patient, highlighted the chronic nature of this issue. "The unavailability problem has persisted for the last five to six years. Occasionally, the drug can be procured locally and supplied for brief periods—perhaps a week—but there is no consistent, reliable supply in public hospitals."
Officials at LHMC acknowledged the procurement challenges. "The injections are imported, and we initiated a tender for procurement three months ago but received no responses," they stated. "We have attempted sourcing through local purchases as well, but availability remains inconsistent. While we provide the injections free of cost when available, there is limited action we can take in the current circumstances."
The Vicious Cycle of Iron Overload
Families are consequently forced to turn to the private market, where prices are prohibitively high. For thalassemia patients, this creates a dangerous cycle: more blood transfusions increase iron overload in the body, and without drugs like Desferal (deferoxamine), this excess iron can cause severe damage to vital organs, including the heart and liver.
Patient advocacy groups report that repeated appeals to authorities have yielded little improvement. "As World Thalassemia Day approaches on May 8, this situation serves as a critical wake-up call," said Deepak Chopra, president of Thalassemics India. "A lifesaving medication has been absent from government hospitals for years. It is no longer under patent and should be available as a generic drug. We cannot afford to lose lives due to drug shortages while claiming to be the pharmacy of the world."
Contradictory Official Statements
Government responses present a conflicting narrative. In Parliament, authorities have asserted there is no shortage. A 2025 Rajya Sabha reply specifically stated that no shortages of thalassemia drugs had been reported in major hospitals. Similarly, in 2016, officials indicated that complaints were limited and the manufacturer had confirmed adequate supply.
A communication from the National Pharmaceutical Pricing Authority in May 2025 reiterated that the manufacturer reported sufficient stock. A Novartis spokesperson also confirmed that currently there is no shortage of Desferal in India.
However, Chopra countered these claims, emphasizing the practical realities. "It is easy to hide behind the assertion that the drug is 'available,' but for a daily-wage worker with a thalassemic child, asking them to purchase even a single vial from a chemist is utterly unrealistic. The government must investigate why the manufacturer is not participating in tenders."
Medical Consequences of Inaccessibility
Medical professionals stress the critical importance of Desferal for managing iron overload. Without regular access, complications can escalate rapidly, leading to organ failure and increased mortality rates.
For Aman and countless others, the issue is starkly clear: when the drug disappears from hospital shelves, their margin for survival diminishes accordingly. This ongoing crisis underscores significant gaps in India's healthcare infrastructure, particularly for patients with chronic conditions requiring consistent, affordable medication.
